Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switching from Biktarvy to long-acting cabotegravir + rilpivirine every two months in virologically suppressed adults with HIV-1
jRCT2080225332Phase 3Completed
- Sponsor
- GSK
- Start
- Aug 2020
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, open-label trial of cabotegravir, rilpivirine and bictegravir + emtricitabine + tenofovir alafenamide in Human immunodeficiency virus infection type 1 (2 arms), sponsored by GSK. Primary endpoints: Virologic suppression at 12 months and Safety and tolerability. Started Aug 2020; status: completed.
02
Drugs
cabotegravirrilpivirinebictegravir + emtricitabine + tenofovir alafenamide
03
Conditions
Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on jRCT2080225332.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080225332.